Adam Garczarczyk

• • Therapy areas: Alzheimer's disease, ALS, SMA, multiple sclerosis

• • Markets: Global

• • Designed and delivered global pre-launch valu e-based pricing strategy for a next generation Alzheimer's asset and lifecycle pricing strategy for the SMA franchise, integrating scientific evidence, market intelligence, financial and launch excellence standards

• • Built unified global pricing governance framework ensuring alignment, quality, transparent decision-making, and seamless execution across diverse international markets

• • Led pivotal pricing and innovative contracting primary research projects to inform price corridors, willingness-to-pay, and contracting options for key development assets

• • Collaborated closely with global value evidence, HEOR, medical, commercial, legal and public affairs teams to embed pricing and access considerations in global brand plans

• • Provided strategic pricing inputs to multiple business development projects

• • Managed a team of three pricing managers, including mentoring and competencies development

• • Therapy areas: SMA, multiple sclerosis

• • Markets: Europe, Canada, APAC, LATAM, and partner markets

• • Developed and led new regional price governa nce processes focusing on optimization of price levels and rebates/discount structures across established and emerging markets

• • Advised senior leadership, governance committees, and guided local teams on 100+ exception cases and reimbursement scenarios annually, balancing access objectives with profitability

• • Rolled out pricing, market access, and reimbursement strategies for MS and SMA portfolios ensuring fit-for-purpose local adaptations, global alignment and consistency

• • Directed affiliate access teams on developmen t of innovative contracting proposals, including value-based and outcome-based models, aligned with corporate access goals

• • Orchestrated payer negotiation strategy trainings and coached affiliate teams on execution tactics

• • Implemented uniform international reference pricing guidance as well as pricing monitoring and insights tools, ensuring critical awareness throughout organisation

• • Developed training and capability-building resources for regional and local market access teams

• • Therapy areas: diabetes, haemophilia, growth hormone disorders

• • Markets: Europe

• • Created and deployed regional pricing governance frameworks establishing consistent approval workflows, documentation standards, and decision processes across European markets

• • Developed and executed biosimilar defence strategies, protecting franchise value through competitive pricing positioning and payer com munication

• • Implemented innovative contracting and access solutions in response to evolving payer expectations and healthcare reforms across EU markets

• • Led pricing, market access, supply chain initia tives, and supported business development projects

• • Optimized launch sequencing and internationa l reference pricing execution, minimizing potential price erosion and maintaining long-term value

• • Provided negotiation tactics supporting regional and local teams in complex pricing discussions

• • Built and led high-performing multicultural team of pricing analysts providing day-to-day guidance and supporting professional development